Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab

Maria Thor,Annemarie F. Shepherd,Isabel Preeshagul,Michael Offin,Daphna Y. Gelblum,Abraham J. Wu,Aditya Apte,Charles B. Simone,Matthew D. Hellmann,Andreas Rimner,Jamie E. Chaft,Daniel R. Gomez,Joseph O. Deasy,Narek Shaverdian

Radiotherapy and Oncology（2022）

引用 9|浏览9

暂无评分

摘要

•Pre-treatment peripheral immune measures predict progression-free survival (PFS) after concurrent chemo-radiation (cCRT) and consolidative immune checkpoint inhibitor (ICI) therapy.•Peripheral immune measures after cCRT present a weaker association with PFS than baseline immune measurres.•Risk-scores from published models on radiation dose to immune-bearing organs were not associated with PFS but with radiation-associated lymphopenia.

查看译文

关键词

Non-small cell lung cancers,Lymphopenia,Chemoradiation,Neutrophil-to-lymphocyte ratio,Cardiopulmonary irradiation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要